SLC26A9: A Potential Drug Target and Biomarker (G115019)

Target Name: SLC26A9

NCBI ID: G115019

SLC26A9

SLC26A9: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 26 (SLC26A9) is a protein that is expressed in most tissues and is involved in the transport of both sodium and glucose across cell membranes. It is a member of the SLC transporter family 26, which is known for its role in the transport of a variety of molecules, including drugs and other small molecules. SLC26A9 is the gene that encodes the protein.

SLC26A9 has been identified as a potential drug target due to its involvement in the transport of a variety of molecules across cell membranes. Many drugs work by modulating the transport of these molecules, either by improving or by inhibiting the transport. For example, some drugs work by increasing the amount of sodium that enters a cell, while others work by decreasing the amount of glucose that enters a cell. By targeting SLC26A9, drugs can potentially affect the transport of other molecules and lead to therapeutic effects.

In addition to its potential as a drug target, SLC26A9 has also been identified as a potential biomarker. The SLC26A9 gene is expressed in most tissues and is highly conserved across species, which makes it a good candidate for use as a gene expression marker. By detecting the expression of SLC26A9, researchers can potentially monitor the effectiveness of drugs on a patient's cells and determine whether the drug is having the desired therapeutic effect.

SLC26A9 has been shown to be involved in a variety of cellular processes. For example, it has been shown to be involved in the regulation of ion channels, which are responsible for the flow of electrical currents through cell membranes. Ion channels are critical for the proper functioning of many cellular processes, including the transport of molecules across cell membranes. By modulating the ion channels that are responsible for these processes, SLC26A9 may be involved in the regulation of a wide range of cellular processes.

SLC26A9 has also been shown to be involved in the regulation of cell signaling pathways. Many cellular signaling pathways rely on the transport of molecules across cell membranes to function properly. SLC26A9 may be involved in the regulation of these signaling pathways by modulating the transport of molecules across cell membranes.

In conclusion, SLC26A9 is a protein that is involved in the transport of sodium and glucose across cell membranes and has been identified as a potential drug target and biomarker. Its involvement in cellular processes such as ion channels and signaling pathways makes it a promising target for drug development. Further research is needed to fully understand the role of SLC26A9 in cellular processes and to develop effective drugs that can target this protein.

Protein Name: Solute Carrier Family 26 Member 9

Functions: DIDS- and thiosulfate- sensitive anion exchanger mediating chloride, sulfate and oxalate transport (PubMed:11834742). Mediates chloride/bicarbonate exchange or chloride-independent bicarbonate extrusion thus assuring bicarbonate secretion (PubMed:15800055). May prefer chloride anions and mediate uncoupled chloride anion transport in an alternate-access mechanism where a saturable binding site is alternately exposed to either one or the other side of the membrane (By similarity)

The "SLC26A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC26A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets